X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (71584) 71584
Government Document (127) 127
Newspaper Article (70) 70
Book Chapter (67) 67
Newsletter (41) 41
Magazine Article (34) 34
Book / eBook (19) 19
Dissertation (17) 17
Conference Proceeding (14) 14
Publication (11) 11
Book Review (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (66250) 66250
female (45211) 45211
breast cancer (26205) 26205
oncology (22670) 22670
animals (22112) 22112
cancer (21120) 21120
cell line, tumor (20424) 20424
biochemistry & molecular biology (20184) 20184
breast neoplasms - pathology (20134) 20134
breast-cancer (16487) 16487
breast neoplasms - metabolism (14229) 14229
middle aged (13093) 13093
mice (13036) 13036
expression (12634) 12634
cell biology (12409) 12409
breast neoplasms - genetics (11846) 11846
breast neoplasms - drug therapy (10720) 10720
adult (10237) 10237
aged (10034) 10034
tumors (9942) 9942
apoptosis (9890) 9890
male (9839) 9839
metastasis (9531) 9531
research (8941) 8941
gene expression (7883) 7883
proteins (7507) 7507
gene expression regulation, neoplastic (7456) 7456
prognosis (7162) 7162
immunohistochemistry (6808) 6808
tumor cells, cultured (6743) 6743
analysis (6651) 6651
breast neoplasms - chemistry (6452) 6452
antineoplastic agents - pharmacology (6266) 6266
genetic aspects (6045) 6045
chemotherapy (5847) 5847
signal transduction (5831) 5831
cells (5714) 5714
research article (5709) 5709
health aspects (5555) 5555
care and treatment (5293) 5293
pharmacology & pharmacy (5250) 5250
medicine (5245) 5245
carcinoma (5146) 5146
cell proliferation (5066) 5066
genetics & heredity (4997) 4997
cell proliferation - drug effects (4976) 4976
growth (4973) 4973
apoptosis - drug effects (4883) 4883
mcf-7 cells (4444) 4444
multidisciplinary sciences (4250) 4250
activation (4179) 4179
development and progression (4164) 4164
mice, nude (4124) 4124
aged, 80 and over (4069) 4069
pathology (3965) 3965
phosphorylation (3965) 3965
mutation (3961) 3961
risk factors (3875) 3875
breast (3792) 3792
biology (3759) 3759
in-vitro (3706) 3706
gene-expression (3684) 3684
biochemistry (3649) 3649
genes (3641) 3641
physiological aspects (3576) 3576
survival (3547) 3547
cancer therapies (3521) 3521
therapy (3499) 3499
protein (3482) 3482
biomarkers, tumor - analysis (3413) 3413
kinases (3407) 3407
cell cycle (3387) 3387
science (3369) 3369
inhibition (3298) 3298
neoplasm metastasis (3289) 3289
antineoplastic agents - therapeutic use (3284) 3284
neoplasms - metabolism (3262) 3262
proliferation (3222) 3222
gene (3174) 3174
neoplasms - pathology (3166) 3166
neoplasms - drug therapy (3159) 3159
cancer research (3123) 3123
cell survival - drug effects (3092) 3092
neoplasm invasiveness (3057) 3057
medicine, research & experimental (3052) 3052
estrogen (3040) 3040
molecular sequence data (3018) 3018
chemistry, medicinal (2982) 2982
in-vivo (2978) 2978
metastases (2969) 2969
identification (2924) 2924
mice, inbred balb c (2904) 2904
chemistry, multidisciplinary (2897) 2897
cancer cells (2879) 2879
antineoplastic agents - chemistry (2846) 2846
receptors, estrogen - analysis (2832) 2832
biophysics (2824) 2824
biomarkers (2820) 2820
blotting, western (2774) 2774
neoplasm staging (2720) 2720
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (71370) 71370
Japanese (315) 315
French (220) 220
Chinese (218) 218
German (97) 97
Russian (92) 92
Spanish (83) 83
Italian (55) 55
Portuguese (51) 51
Hungarian (34) 34
Polish (26) 26
Czech (18) 18
Dutch (18) 18
Norwegian (18) 18
Romanian (7) 7
Serbian (5) 5
Croatian (4) 4
Bulgarian (3) 3
Ukrainian (3) 3
Danish (2) 2
Hebrew (2) 2
Swedish (2) 2
Arabic (1) 1
Korean (1) 1
Lithuanian (1) 1
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature cell biology, ISSN 1476-4679, 2018, Volume 20, Issue 8, pp. 954 - 965
BRCA1 deficiencies cause breast, ovarian, prostate and other cancers, and render tumours hypersensitive to poly(ADP-ribose) polymerase (PARP) inhibitors. To... 
PATHWAY CHOICE | STRAND BREAK REPAIR | RESECTION | DAMAGE-RESPONSE | 53BP1 | CLASS-SWITCH RECOMBINATION | FANCONI-ANEMIA | DIFFERENTIAL EXPRESSION ANALYSIS | POLYMERASE-ZETA | TELOMERES | CELL BIOLOGY | Osteosarcoma - drug therapy | Mad2 Proteins - metabolism | Humans | Multiprotein Complexes | Ovarian Neoplasms - pathology | Bone Neoplasms - pathology | DNA Breaks, Double-Stranded | Bone Neoplasms - metabolism | Breast Neoplasms - metabolism | Dose-Response Relationship, Drug | Ovarian Neoplasms - genetics | Telomere-Binding Proteins - genetics | DNA End-Joining Repair | HEK293 Cells | Female | Bone Neoplasms - genetics | Ovarian Neoplasms - metabolism | Bone Neoplasms - drug therapy | BRCA1 Protein - deficiency | Telomere-Binding Proteins - metabolism | Ovarian Neoplasms - drug therapy | Osteosarcoma - metabolism | DNA-Binding Proteins | Tumor Suppressor p53-Binding Protein 1 - metabolism | Recombinational DNA Repair | Tumor Suppressor p53-Binding Protein 1 - genetics | Cisplatin - pharmacology | Breast Neoplasms - drug therapy | Proteins - genetics | Xenograft Model Antitumor Assays | BRCA1 Protein - genetics | Poly(ADP-ribose) Polymerase Inhibitors - pharmacology | Drug Resistance, Neoplasm - genetics | Animals | Breast Neoplasms - genetics | Proteins - metabolism | Breast Neoplasms - pathology | Mad2 Proteins - genetics | Cell Line, Tumor | Mice | Osteosarcoma - genetics | Cell Cycle Proteins | Osteosarcoma - pathology | Care and treatment | DNA | Cancer cells | Breast cancer | Genetic aspects | Research | Gene expression | Single-stranded DNA | DNA damage | Homologous recombination | Poly(ADP-ribose) | Homology | Genomes | Inactivation | Proteins | Ribose | Null cells | Deoxyribonucleic acid--DNA | BRCA2 protein | CRISPR | Deactivation | BRCA1 protein | Poly(ADP-ribose) polymerase | Adenosine diphosphate | Oligosaccharides | Double-strand break repair | Screens | Cisplatin | Inhibitors | Prostate | Viability | Tumors | Telomere-Binding Proteins / metabolism | Osteosarcoma / genetics | Telomere-Binding Proteins / genetics | BRCA1 Protein / genetics | Cellular Biology | Genetics | Proteins / genetics | Osteosarcoma / drug therapy | Ovarian Neoplasms / genetics | Mad2 Proteins / genetics | Proteins / metabolism | Breast Neoplasms / drug therapy | Breast Neoplasms / metabolism | Tumor Suppressor p53-Binding Protein 1 / genetics | BRCA1 Protein / deficiency | Ovarian Neoplasms / metabolism | Mad2 Proteins / metabolism | Breast Neoplasms / pathology | Bone Neoplasms / genetics | Ovarian Neoplasms / pathology | Bone Neoplasms / pathology | Life Sciences | Bone Neoplasms / drug therapy | Ovarian Neoplasms / drug therapy | Osteosarcoma / metabolism | Biochemistry, Molecular Biology | Breast Neoplasms / genetics | Drug Resistance, Neoplasm / genetics | Osteosarcoma / pathology | Bone Neoplasms / metabolism | Poly(ADP-ribose) Polymerase Inhibitors / pharmacology | Cisplatin / pharmacology | Molecular biology | Tumor Suppressor p53-Binding Protein 1 / metabolism | Cancer
Journal Article
The lancet oncology, ISSN 1470-2045, 2017, Volume 18, Issue 1, pp. 75 - 87
Summary Background Poly(ADP-ribose) polymerase (PARP) inhibitors have activity in ovarian carcinomas with homologous recombination deficiency. Along with BRCA1... 
Hematology, Oncology and Palliative Medicine | POLY(ADP-RIBOSE) POLYMERASE | OLAPARIB | ONCOLOGY | HOMOLOGOUS RECOMBINATION DEFICIENCY | MUTANT-CELLS | DNA-REPAIR | CANCER | HETEROZYGOSITY | TUMORS | BREAST | GENOMIC LOSS | Prognosis | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Ovarian Neoplasms - pathology | Salvage Therapy | Neoplasm Recurrence, Local - drug therapy | Germ-Line Mutation - genetics | Neoplasm Recurrence, Local - pathology | Ovarian Neoplasms - genetics | Neoplasms, Glandular and Epithelial - genetics | Peritoneal Neoplasms - drug therapy | Fallopian Tube Neoplasms - genetics | Female | Antineoplastic Agents - pharmacology | Poly(ADP-ribose) Polymerases - chemistry | Ovarian Neoplasms - drug therapy | Platinum - pharmacology | Fallopian Tube Neoplasms - drug therapy | Peritoneal Neoplasms - pathology | Neoplasms, Glandular and Epithelial - pathology | Fallopian Tube Neoplasms - pathology | Survival Rate | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | BRCA1 Protein - genetics | International Agencies | Peritoneal Neoplasms - genetics | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Indoles - therapeutic use | Neoplasm Recurrence, Local - genetics | Aged | Neoplasm Staging | BRCA2 Protein - genetics | Drug Resistance, Neoplasm - drug effects | Sugars | Monosaccharides | Ovarian cancer | Analysis | Carcinoma | Cancer
Journal Article
Journal Article
European journal of cancer (1990), ISSN 0959-8049, 2016, Volume 68, pp. 156 - 162
Abstract Purpose To assess preliminary safety and efficacy results of the anti-programmed cell death ligand-1 (anti-PD-L1) durvalumab in combination with... 
Hematology, Oncology and Palliative Medicine | Immunoradiotherapy | Phase 2 | Phase 1 | Radiotherapy | Anti-PD-L1 | ABSCOPAL | ONCOLOGY | MECHANISMS | PATIENT | RADIATION-THERAPY | Lymphatic Metastasis - radiotherapy | Bone Neoplasms - therapy | Carcinoma, Squamous Cell - pathology | Humans | Middle Aged | Carcinoma, Transitional Cell - secondary | Radiosurgery | Bone Neoplasms - secondary | Antibodies, Monoclonal - therapeutic use | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Carcinoma, Transitional Cell - therapy | Liver Neoplasms - therapy | Eye Neoplasms - therapy | Chemoradiotherapy | Small Cell Lung Carcinoma - secondary | Breast Neoplasms - therapy | Brain Neoplasms - secondary | Neoplasms - therapy | Squamous Cell Carcinoma of Head and Neck | Urinary Bladder Neoplasms - pathology | Aged, 80 and over | Adult | Female | Liver Neoplasms - secondary | Colonic Neoplasms - therapy | Eye Neoplasms - pathology | Head and Neck Neoplasms - therapy | Kaplan-Meier Estimate | Carcinoma, Squamous Cell - therapy | Survival Rate | Lung Neoplasms - therapy | Adenocarcinoma - secondary | Melanoma - secondary | Head and Neck Neoplasms - pathology | Disease-Free Survival | B7-H1 Antigen - antagonists & inhibitors | Adenocarcinoma - therapy | Breast Neoplasms - pathology | Colonic Neoplasms - pathology | Urinary Bladder Neoplasms - therapy | Brain Neoplasms - therapy | Radiotherapy, Conformal | Aged | Small Cell Lung Carcinoma - therapy | Melanoma - therapy | Biochemistry | Apoptosis
Journal Article
Nature communications, ISSN 2041-1723, 2015, Volume 6, Issue 1, p. 8839
Journal Article
Nature chemical biology, ISSN 1552-4469, 2014, Volume 10, Issue 7, pp. 558 - 566
PTP1B, a validated therapeutic target for diabetes and obesity, has a critical positive role in HER2 signaling in breast tumorigenesis. Efforts to develop... 
LAPATINIB | OVEREXPRESSION | TYROSINE-PHOSPHATASE 1B | BIOCHEMISTRY & MOLECULAR BIOLOGY | ACQUIRED-RESISTANCE | BINDING-SITE | MECHANISMS | INDUCTION | HUMAN BREAST-CANCER | CONTRIBUTES | TUMORS | Receptor, ErbB-2 - genetics | Humans | Gene Expression Regulation, Neoplastic | Receptor, ErbB-2 - metabolism | Molecular Targeted Therapy | Mammary Neoplasms, Experimental - genetics | Breast Neoplasms - enzymology | Protein Binding - drug effects | Mammary Neoplasms, Experimental - pathology | Female | Antineoplastic Agents - pharmacology | Protein Tyrosine Phosphatase, Non-Receptor Type 1 - genetics | Mammary Neoplasms, Experimental - enzymology | Spermine - analogs & derivatives | Mammary Neoplasms, Experimental - drug therapy | Allosteric Regulation - drug effects | Protein Structure, Tertiary | Catalytic Domain | Protein Structure, Secondary | Signal Transduction | Allosteric Site - drug effects | Protein Tyrosine Phosphatase, Non-Receptor Type 1 - antagonists & inhibitors | Spermine - chemistry | Models, Molecular | Antineoplastic Agents - chemistry | Breast Neoplasms - drug therapy | Protein Tyrosine Phosphatase, Non-Receptor Type 1 - metabolism | Animals | Breast Neoplasms - genetics | Spermine - pharmacology | Breast Neoplasms - pathology | Cholestanes - chemistry | Cholestanes - pharmacology | Mice | Kinetics | Breast cancer | Tumorigenesis | Diabetes | Drug therapy | Cholestanes | Allosteric Regulation | Breast Neoplasms | Life Sciences | Biomolecules | Biochemistry, Molecular Biology | Antineoplastic Agents | Spermine | Protein Tyrosine Phosphatase, Non-Receptor Type 1 | Mammary Neoplasms, Experimental | Allosteric Site | Protein Binding | Receptor, ErbB-2
Journal Article
Nature communications, ISSN 2041-1723, 2018, Volume 9, Issue 1, pp. 2612 - 11
The C-X-C chemokine receptor type 4 (CXCR4, CD184) pathway is a key regulator of cancer metastasis. Existing therapeutics that block CXCR4 signaling are... 
MIGRATION | D-AMINO ACIDS | CELLS | IN-VITRO | PROTEIN | RECOGNITION | CHOLESTEROL | MULTIDISCIPLINARY SCIENCES | DIMERIZATION | EXPRESSION | CXCR4 RECEPTOR | Luciferases - metabolism | Membrane Microdomains - metabolism | Humans | Lung Neoplasms - metabolism | Polyethylene Glycols - chemistry | Triple Negative Breast Neoplasms - drug therapy | Brain Neoplasms - metabolism | Luciferases - genetics | Antineoplastic Agents - metabolism | Brain Neoplasms - secondary | Peptides - metabolism | Lung Neoplasms - secondary | Triple Negative Breast Neoplasms - pathology | Female | Receptors, CXCR4 - genetics | Antineoplastic Agents - pharmacology | Liver Neoplasms - secondary | Genes, Reporter | Binding, Competitive | Liver Neoplasms - prevention & control | Lung Neoplasms - genetics | Gene Expression | Liver Neoplasms - genetics | Peptides - chemistry | Brain Neoplasms - genetics | Phosphatidylcholines - chemistry | Antineoplastic Agents - chemistry | Peptides - pharmacology | Receptors, CXCR4 - metabolism | Brain Neoplasms - prevention & control | Xenograft Model Antitumor Assays | Liposomes - chemistry | Animals | Triple Negative Breast Neoplasms - genetics | Lung Neoplasms - prevention & control | Membrane Microdomains - drug effects | Mice, Nude | Triple Negative Breast Neoplasms - metabolism | Liver Neoplasms - metabolism | Cell Line, Tumor | Protein Binding | Liposomes - metabolism | Mice | Phosphatidylethanolamines - chemistry | Cell Movement | Binding | Peptides | Gene regulation | Rafts | Lipid rafts | Breast cancer | Metastasis | Gene expression | Density | CXCR4 protein | Molecular chains | Cell adhesion & migration | Metastases | Signaling | CD18 antigen | Dimers | Liposomes | Cell migration | Cancer
Journal Article
International journal of molecular sciences, ISSN 1422-0067, 2019, Volume 20, Issue 23, p. 6047
The skeletal system is the third most common site for cancer metastases, surpassed only by the lungs and liver. Many tumors, especially those of the breast,... 
multimodal pain treatment | nociceptive pain | BIOCHEMISTRY & MOLECULAR BIOLOGY | METASTASES | CELL GLUTAMATE RELEASE | CLINICAL-FEATURES | CHEMISTRY, MULTIDISCIPLINARY | RAT MODEL | NERVE GROWTH-FACTOR | BREAST-CANCER | neuropathic pain | cancer-induced bone pain | SYSTEM X(C)(-) | PROSTATE-CANCER | DISEASE | DOUBLE-BLIND | Bone Neoplasms - therapy | Humans | Gamma Rays - therapeutic use | Bone Neoplasms - secondary | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Prostatic Neoplasms - physiopathology | Lung Neoplasms - physiopathology | Neuralgia - pathology | Breast Neoplasms - physiopathology | Prostatic Neoplasms - therapy | Breast Neoplasms - therapy | Cancer Pain - pathology | Kidney Neoplasms - physiopathology | Musculoskeletal Pain - pathology | Musculoskeletal Pain - therapy | Bone Neoplasms - physiopathology | Diphosphonates - therapeutic use | Female | Musculoskeletal Pain - physiopathology | Neuralgia - psychology | Quality of Life - psychology | Neuralgia - physiopathology | Kidney Neoplasms - psychology | Kidney Neoplasms - therapy | Analgesics - therapeutic use | Bone Neoplasms - psychology | Prostatic Neoplasms - pathology | Cancer Pain - physiopathology | Pain Management - methods | Lung Neoplasms - therapy | Prostatic Neoplasms - psychology | Musculoskeletal Pain - psychology | Cancer Pain - therapy | Breast Neoplasms - pathology | Breast Neoplasms - psychology | Kidney Neoplasms - pathology | Cancer Pain - psychology | Lung Neoplasms - psychology | Neuralgia - therapy
Journal Article
Breast cancer research and treatment, ISSN 1573-7217, 2013, Volume 141, Issue 1, pp. 89 - 99
Lysyl oxidase-like 2 (LOXL2) is associated with invasiveness and metastasis in breast cancer. We analyzed the prognostic impact of LOXL2 for breast cancer... 
Oncology | Breast cancer | Medicine & Public Health | Invasiveness | Triple negative | LOXL2 | LYSYL OXIDASE | LYSYL-OXIDASE-LIKE-2 | PROTEIN | GENE | ONCOLOGY | STATISTICS | Humans | Middle Aged | Carcinoma - mortality | Carcinoma - chemistry | Amino Acid Oxidoreductases - genetics | Breast Neoplasms - chemistry | Neoplasm Metastasis | Carcinoma in Situ - genetics | Laminin | RNA Interference | Amino Acid Oxidoreductases - analysis | Neoplasm Proteins - genetics | Proteoglycans | Carcinoma in Situ - pathology | Triple Negative Breast Neoplasms - mortality | Breast Neoplasms - genetics | Survival Analysis | Cell Line, Tumor | Carcinoma - genetics | Carcinoma in Situ - mortality | Cell Movement | Carcinoma in Situ - chemistry | Prognosis | Tissue Array Analysis | Gene Expression Regulation, Neoplastic | Triple Negative Breast Neoplasms - chemistry | In Situ Hybridization | Epithelial-Mesenchymal Transition | Triple Negative Breast Neoplasms - pathology | Adult | Female | Neoadjuvant Therapy | Carcinoma - pathology | Neoplasms, Multiple Primary - mortality | Neoplasms, Multiple Primary - genetics | Phyllodes Tumor - genetics | Neoplasm Invasiveness | Neoplasm Proteins - biosynthesis | RNA, Small Interfering - pharmacology | Kaplan-Meier Estimate | Phyllodes Tumor - mortality | Proportional Hazards Models | Neoplasms, Multiple Primary - pathology | Disease-Free Survival | Phyllodes Tumor - chemistry | Phyllodes Tumor - pathology | Triple Negative Breast Neoplasms - genetics | Breast Neoplasms - pathology | Collagen | Breast Neoplasms - mortality | Neoplasm Proteins - analysis | Neoplasms, Multiple Primary - chemistry | Amino Acid Oxidoreductases - biosynthesis | Drug Combinations | Oxidases | Care and treatment | Cancer patients | Analysis | Patient outcomes | Development and progression
Journal Article
Cochrane library, ISSN 1465-1858, 2009, Volume 2016, Issue 9, p. CD005004
Journal Article